Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas

Inclusion Criteria:

Refractory to or relapsed after at least 1 prior treatment line.
Eastern Cooperative Oncology Group (ECOG) performance status ≤2
Patients must be ≥18 years of age
Able to give a written informed consent.

Exclusion Criteria:

Patients receiving cancer therapy within 3 weeks prior to Cycle1 Day1 (C1D1).
Patients with active Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Human immune deficiency virus (HIV) infection
Patients who received Allo-Stem cell Transplantation(Allo-SCT) within 12 months.
Patients with graft versus-host disease (GVHD)
Subjects who have received drugs that directly or indirectly inhibit calcineurin or Nuclear Factor of activated T cells (NFAT) activity .
Patient with symptomatic, or history of documented congestive heart failure (NY Heart Association functional classification III-IV);
Patient with Frederica's (QTcF) formulas (QTcF) ≥450 msec;
Patient with angina not well-controlled by medication;
Women who are pregnant or lactating.